On Thursday, Shares of Hecla Mining Company (NYSE:HL), subtract -12.43% and closed at $6.34 in the last trading session. The last trading range of the stock ranges between $6.29 and $7.08. The company’s Market capitalization is $2.53 Billion with the total Outstanding Shares of 395.29 million. Hecla Mining Company (NYSE:HL) recently declared third quarter financial and operating results.
THIRD QUARTER HIGHLIGHTS AND NOTEWORTHYITEMS (contrast to Q3 2015)
Net income applicable to common shareholders of $25.7 million, or $0.07 per share.
Sales of $179.4 million, up 71%, a record.
Adjusted EBITDA of $75.2 million, up 323%.1
Cash offered by operating activities of $87.0 million, up 225%. Includes $16 million of insurance proceeds for the Troy Mine reclamation.
Free cash flow of $27.7 million, up $38 million.2
Total silver production of 4.3 million ounces, up 67%.
Gold production of 52,126 ounces, up 19%.
Silver equivalent production of 10.3 million ounces, up 17%.3
Last 12 months net loss of $13.7 million and adjusted EBITDA of $234 million.1
Net debt/adjusted EBITDA (last 12 months) of 1.4x, a 49% decline.1,4
Cash and cash equivalents and short-term investments of $192.4 million at September 30, 2016, up $33 million over the second quarter.
Accomplished the acquisition of the Montanore project, located near the Rock Creek project.
Reduced estimate for 2016 cash cost, after by-product credits, per silver ounce to $4.00 and raised estimate for 2016 cash cost, after by-product credits, per gold ounce to $750.5
Technical Analysis: During the 52-week trading session the minimum price at which share price traded, registered at $1.45 and reached to max level of $7.64. The EPS of company is strolling at -0.04.
Shares of Merck & Co., Inc.(NYSE:MRK), jumped 1.22% and closed at $64.96 in the last trading session. The last trading range of the stock ranges between $64.52 and $65.46. The company’s Market capitalization is $189.97 Billion with the total Outstanding Shares of 2.76 billion. Merck (MRK), known as MSD outside the United States and Canada, recently declared that new data investigating the use of KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, in patients with formerly treated advanced urothelial cancer will be presented at the Society for Immunotherapy of Cancer’s (SITC) 31st Annual Meeting, Nov. 9-13. Data on overall survival (OS) and progression-free survival (PFS) from the phase 3 KEYNOTE-045 study – investigating KEYTRUDA contrast to investigator’s choice chemotherapy in patients with metastatic or locally advanced or unresectable urothelial cancer that has recurred or progressed following platinum-based chemotherapy – will be presented for the first time; these data were accepted as a late-breaking abstract. In addition, results from three different studies exploring the utility of various biomarkers for KEYTRUDA will be presented at the meeting.
Technical Analysis: During the 52-week trading session the minimum price at which share price traded, registered at $47.97 and reached to max level of $65.46. The EPS of company is strolling at 1.97.